<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005458</url>
  </required_header>
  <id_info>
    <org_study_id>TB1309CSF</org_study_id>
    <nct_id>NCT02005458</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy</brief_title>
  <official_title>Multi-center, Randomized, Open-labeled, Positive-controlled, Phase Ⅱ Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Amoytop Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiamen Amoytop Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to examine which dose of YPEG-rhG-CSF, once-per-cycle, has similar efficacy and
      safety, comparing to PEG-rhG-CSF, once-per-cycle, in chemotherapy-induced neutropenia
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Grade 3 &amp;4 neutropenia, and median duration of neutropenia in the two experimental cycles</measure>
    <time_frame>21 day</time_frame>
    <description>Grade 3 and 4 neutropenia means absolute neutrophil count is less than 1000/mm3 and 500/mm3 , respectively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia in the two experimental cycles</measure>
    <time_frame>21 day</time_frame>
    <description>Febrile neutropenia means absolute neutrophil count is less than 500/mm3 or absolute neutrophil count between 500/mm3 and 1000mm3 but probably to decline to less than 500mm3 within 48hrs, and body temperature is higher than 38.5 degrees celsius or higher than 38.0 degrees celsius and lasting for more than 1hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diversification of neutrophil in the two experimental cycles</measure>
    <time_frame>21 day</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>YPEG-rhG-CSF 20μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YPEG-rhG-CSF 30μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YPEG-rhG-CSF 45μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-rhG-CSF 100μg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle</intervention_name>
    <arm_group_label>YPEG-rhG-CSF 20μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle</intervention_name>
    <arm_group_label>YPEG-rhG-CSF 30μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle</intervention_name>
    <arm_group_label>YPEG-rhG-CSF 45μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle</intervention_name>
    <arm_group_label>PEG-rhG-CSF 100μg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non-small cell lung cancer or Breast cancer, and adequate for carboplatin
             combined with taxol or cyclophosphamide combined with pharmorubicin chemotherapy

          -  Karnofsky Score ≥ 70

          -  Life Expectancy &gt; 3 months

          -  Age: 18～70yrs.

          -  Peripheral blood test: WBC≥3.5×106/mm3, PLT≥100×106/mm3, ANC≥1.5×106/mm3; Normal bone
             marrow function; Bone marrow biopsy shows active hematopoietic without cancer cells.

          -  Normal coagulation function, no evidences of hemorrhage tendency.

          -  No exiting diseases or condition that may influence drug absorption, distribution,
             metabolism, and excretion.

          -  Adequate liver, cardiac, kidney function. Indicators of liver function test ≤ 2.5ULN,
             Indicators of kidney function test ≤ 1ULN

          -  Understand and voluntarily sign an informed consent form.

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Evidence of tumor metastasis in bone marrow

          -  Lack insight due to tumor metastasis in the central nervous system

          -  Prior bone marrow transplant or stem cell transplant

          -  Infective symptom before enrollment into this study

          -  Other malignancy history

          -  Known hypersensitivity to any component of the drug(e.g. rh-G-CSF) that to be
             administered

          -  Subject enrolled in any other investigational drug or device trial within 3 months of
             informed consent date

          -  Drug abuser or alcoholist

          -  Prior radiotherapy or expected to received radiotherapy

          -  Unstable or uncontrolled cardiac or hypertension

          -  Other conditions which in the opinion of the investigator preclude enrollment into the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhangzhou Municipal Hospital of Fujian Province</name>
      <address>
        <city>Zhangzhou</city>
        <state>Fujian</state>
        <zip>363000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaaxi Provincial Tumor Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, CAMS</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian cancer hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuzhou General Hospital of Nanjing Military Command</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College Huazhou University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang cancer hospital</name>
      <address>
        <city>Zhejiang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neutropenia</keyword>
  <keyword>Febrile neutropenia</keyword>
  <keyword>PEG-rhG-CSF</keyword>
  <keyword>Myelosuppressive chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

